Amicus Therapeutics Sees Unusually Large Options Volume (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw unusually large options trading activity on Monday. Stock investors purchased 11,013 call options on the stock. This is an increase of 666% compared to the average volume of 1,438 call options.
In other news, insider Jay Barth sold 30,000 shares of Amicus Therapeutics stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the sale, the insider now owns 64,184 shares of the company’s stock, valued at $641,840. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $8.00, for a total transaction of $239,312.00. Following the completion of the sale, the insider now directly owns 474,438 shares in the company, valued at approximately $3,795,504. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its position in shares of Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock worth $685,000 after buying an additional 66,209 shares in the last quarter. Legal & General Group Plc raised its position in shares of Amicus Therapeutics by 1.6% in the second quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock worth $558,000 after buying an additional 852 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Amicus Therapeutics during the second quarter worth about $1,057,000. Rhumbline Advisers raised its position in shares of Amicus Therapeutics by 2.0% in the second quarter. Rhumbline Advisers now owns 138,438 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 2,690 shares in the last quarter. Finally, Smith Asset Management Group LP bought a new position in shares of Amicus Therapeutics during the second quarter worth about $316,000.
Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 12.58 on Thursday. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $14.05. The firm’s market cap is $1.80 billion. The company has a 50 day moving average of $11.40 and a 200 day moving average of $8.12.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. The firm had revenue of $7.16 million during the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 58.10%. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts anticipate that Amicus Therapeutics will post ($1.41) EPS for the current fiscal year.
Several analysts have recently weighed in on FOLD shares. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 2nd. Bank of America Corporation lowered their target price on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $12.00 target price on shares of Amicus Therapeutics in a report on Friday, June 30th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.75.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.